GeneDx (WGS) Stock Price, News & Analysis

Company Overview

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care. In 2015, the company became a subsidiary of OPKO Health, leveraging OPKO’s global infrastructure to expand its testing capabilities and research collaborations. GeneDx holds College of American Pathologists (CAP) accreditation and is CLIA-certified, ensuring adherence to stringent quality and regulatory standards.

GeneDx serves a diverse client base that includes hospitals, academic medical centers, reference laboratories and pharmaceutical partners, as well as patients participating in research studies. While its primary market is the United States, the company also accommodates international referrals through its global network, enabling access to advanced genetic diagnostics for clinicians and patients worldwide. With a dedicated team of geneticists, laboratory scientists and genetic counselors, GeneDx continues to advance precision medicine by translating complex genomic data into actionable clinical insights.

Key Stats

• Today's Range: $84.36 to $87.62
• 50-Day Range: $59.10 to $90.29
• 52-Week Range: $32.21 to $170.87
• Volume: 331,595 shs
• Average Volume: 453,435 shs
• Market Capitalization: $2.54 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $89.57
• Consensus Rating: Moderate Buy

GeneDx Stock Analysis - MarketRank™

GeneDx scored higher than 36% of companies evaluated by MarketBeat, and ranked 626th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

GeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for GeneDx is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

GeneDx has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for GeneDx are expected to grow in the coming year, from ($0.41) to $1.15 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GeneDx is -23.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GeneDx is -23.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GeneDx has a P/B Ratio of 8.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

26.89% of the float of GeneDx has been sold short.

Short Interest Ratio / Days to Cover

GeneDx has a short interest ratio ("days to cover") of 12.43, which indicates bearish sentiment.

Change versus previous month

Short interest in GeneDx has recently decreased by 4.58%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GeneDx does not currently pay a dividend.

Dividend Growth

GeneDx does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.78

News Sentiment

GeneDx has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for GeneDx this week, compared to 8 articles on an average week.

Search Interest

10 people have searched for WGS on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, GeneDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,283,920.00 in company stock.

Percentage Held by Insiders

25.17% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 9/11/2026
• Next Earnings (Estimated): 10/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:WGS
• CIK: 1818331
• Web: sema4.com
• Phone: 800-298-6470
• Fax: N/A
• Employees: 1,300
• Year Founded: 2000

Price Target and Rating

• Average Price Target for GeneDx: $89.57
• High Price Target: $150.00
• Low Price Target: $63.00
• Potential Upside/Downside: +5.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.02 million
• Net Margins: -23.41%
• Pretax Margin: -23.39%
• Return on Equity: 4.12%
• Return on Assets: 2.26%

Debt

• Debt-to-Equity Ratio: 0.40
• Current Ratio: 3.30
• Quick Ratio: 3.06

Sales & Book Value

• Annual Sales: $427.54 million
• Price / Sales: 5.95
• Cash Flow: $2.33 per share
• Price / Cash Flow: 36.63
• Book Value: $10.54 per share
• Price / Book: 8.09

Miscellaneous

• Outstanding Shares: 29,820,000
• Free Float: 22,317,000
• Market Cap: $2.54 billion
• Optionable: Optionable
• Beta: 1.99